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sion is currently performed by staging systems which are not
continuous quantitative measurements. We aimed at assessing
a quantitative measurement of ﬁbrosis collagen proportionate
area (CPA), to evaluate ﬁbrosis progression and compare it to
Ishak stage progression.
Methods:We studied a consecutive cohort of 155 patients with
recurrent HCV hepatitis after liver transplantation (LT), who
had liver biopsies at one year and were subsequently evaluated
for progression of ﬁbrosis using CPA and Ishak staging, and corre-
lated with clinical decompensation. The upper quartile of distri-
bution of ﬁbrosis rates (difference in CPA or Ishak stage
between paired biopsies) deﬁned fast ﬁbrosers.
Results: Patients had 610 biopsies and a median follow-up of 116
(18–252) months. Decompensation occurred in 29 (18%) patients.
Median Ishak stage progression rate was 0.42 units/year: (24
(15%) fast ﬁbrosers). Median CPA ﬁbrosis progression rate was
0.71%/year (36 (23%) fast ﬁbrosers). Clinical decompensation
was independently associated by Cox regression only with CPA
(p = 0.007), with AUROCs of 0.81 (95% CI 0.71–0.91) compared
to 0.68 (95% CI 0.56–0.81) for Ishak stage.
Fast ﬁbrosis deﬁned by CPA progression was independently asso-
ciated with histological de novo hepatitis (OR: 3.77), older donor age
(OR: 1.03) andnon-use/discontinuationof azathioprine before 1 year
post-LT (OR: 3.85), whereas when deﬁned by Ishak progression, fast
ﬁbrosers was only associated with histological de novo hepatitis.
Conclusions: CPA ﬁbrosis progression rate is a better predictor of
clinical outcome than progression by Ishak stage. Histological de
novo hepatitis, older donor age and non-use/discontinuation of
azathioprine are associated with rapid ﬁbrosis progression in
recurrent HCV chronic hepatitis after liver transplantation.Journal of Hepatology 20
Keywords: Digital image analysis; Collagen; Fibrosis progression; Recurrent HCV;
Liver transplantation.
Received 11 June 2012; received in revised form 11 November 2012; accepted 7
December 2012; available online 20 December 2012
⇑ Corresponding author. Address: The Royal Free Sheila Sherlock Liver Centre and
University Department of Surgery, UCL and Royal Free Hospital, Pond Street,
Hampstead, London NW3 2QG, UK. Tel.: +44 20 74726229; fax: +44 20 74726226.
E-mail address: Andrew.Burroughs@nhs.net (A.K. Burroughs).
 These authors contributed equally to this work.by Elsevier B.V. All rights reserved.Introduction
Evaluation of liver ﬁbrosis is an important aspect of the clinical
management of chronic liver disease. Histological assessment is
the reference standard [1], which has been used to assess changes
in ﬁbrosis with therapy, and to validate non-invasive markers of
ﬁbrosis [2].
Currently, all histological scores for staging in chronic viral
hepatitis use categorical systems, which include description of
architectural changes and sites of ﬁbrosis. They do not assess
ﬁbrosis quantitatively [1–3]. These scoring systems distinguish
between the grade and stage of chronic hepatitis, with the stage
used as a measure of ﬁbrosis and architectural changes. Although,
ﬁbrosis is a very important component of stage, the two terms
have been confused [3] and this has led to misinterpretation of
data in the literature, as stages have been evaluated incorrectly
as quantitative estimates of ﬁbrosis and as continuous variables
statistically [1,2]. Indeed, ﬁbrosis progression or regression has
most often been evaluated in terms of a one or two Ishak or
Metavir stage change.
We have published a method using computer-assisted digital
image analysis (DIA) using picroSirius red stained histological sec-
tions to quantify liver collagen [1,4], as the quantity of picroSirius
red correlates well with morphometrically calculated hepatic
ﬁbrosis [5]. The quantitative assessment of collagen is evaluated
as collagen proportionate area. In previous studies, CPA in recur-
rent HCV post-LT correlated with both Ishak stage scores and
HVPG, with greater percentage changes in CPA than in HVPG in
early portal hypertension [6]. CPA at 1-year biopsy post-LT for
HCV cirrhosis was highly predictive of clinical outcome and better
than Ishak stage orHVPG [7]. Lastly, CPAallows subclassiﬁcationof
cirrhosis [8] and this potentially increases the possibility of using
histological parameters in cirrhosis to predict clinical outcomes.
Fibrosis progression before [9,10] and after transplantation
has prognostic signiﬁcance: rapid ﬁbrosis and early cirrhosis
are associated with hepatic decompensation [11–13] and poor13 vol. 58 j 962–968
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survival [14]. Therefore, determination of CPA ﬁbrosis progres-
sion rate could be prognostically useful.
The aims of this study were, ﬁrstly, to deﬁne the best method
for evaluation of ﬁbrosis progression (Ishak stage vs. CPA) with
decompensation being the clinical end point, and secondly to
identify risk factors for ﬁbrosis progression in this population.Patients and methods
Between October 1988 and October 2010, 304 patients were transplanted at the
Royal Free Hospital with end-stage liver disease due to HCV infection (325 trans-
plants): 155 patients with a ﬁrst transplant, who had both a biopsy at one year
(performed between 12–15 months) and at least one additional subsequent fol-
low-up biopsy, were selected for the study. In our centre, patients transplanted
for HCV cirrhosis are scheduled for biopsies at yearly intervals after transplanta-
tion, as part of routine care. If ‘unexplained’ changes in LFTs occur, patients are
also biopsied. The last biopsy during follow-up was used to compare with the
ﬁrst, to assess the ﬁbrosis progression rate adjusted for the time interval between
biopsies. Predictive factors were evaluated with respect to changes in ﬁbrosis
from ﬁrst to last biopsy.
For each patient, the following were recorded (listed in Table 1):
demographic and clinical data, donor age and gender, cold and warm ischaemia
time, initial and one year post-LT immunosuppression, characteristics and
reatment of rejection episodes, the year of transplantation (divided into 3 eras,
n1 = 1988–1994, n2 = 1995–2000, n3 = 2001–2008), cytomegalovirus (CMV)
post-LT infection or any other infection, histological episodes of de novo hepati-
tis (in biopsies performed during follow-up to diagnose causes of abnormal
LFTs), genotype, viral load pre and 1 year post-LT, diabetes mellitus pre and
post-transplant, human leukocyte antigen (HLA), and blood group compatibility
of donor and recipient.
We calculated the percentage of ﬁbrosis change according to CPA (CPA in the
latest biopsy subtracted from CPA at one year in each patient, divided by time in
years between the last and one year biopsy: (CPA last – CPA at one year)/time last –
time at one year: CPA%/year). Ishak stage progression was calculated as stage in
the most recent biopsy subtracted from stage in the biopsy at one year, divided by
time in years – stage ‘‘units’’/year between the two biopsies. If SVR was achieved
at any time point, we evaluated only the last biopsy before starting therapy fol-
lowed by SVR. We also evaluated changes in liver ﬁbrosis at ﬁxed intervals, at
3 and 5 years after liver transplantation, in relation to clinical decompensation,
in order to make the time frame for evaluation more homogenous. The Ishak
stage change calculation was evaluated as it has been used to assess ﬁbrosis pro-
gression in the literature and we wished to compare our results with those of oth-
ers [15,16] [2]. However, we acknowledge that since Ishak stage scores are not
numerical measurements, without an arithmetical relationship between them
(the ‘‘scores’’ are merely categorical labels), this method is an approximation
[1–3]. Fast ﬁbrosers were deﬁned as patients in the upper quartile of the distribu-
tions of ﬁbrosis progression values for either Ishak stage or CPA. The remainder
constituted ‘non-fast ﬁbrosers’.
Clinical decompensation was deﬁned as whichever occurred ﬁrst of either,
ascites/hydrothorax or variceal bleeding or encephalopathy. In the evaluation of
the association of indices of ﬁbrosis progression with clinical decompensation,
we only evaluated the last biopsy before decompensation.
The study protocol conformed to the ethical guidelines of the Declaration of
Helsinki. All patients gave written informed consent for biopsies, HVPG and the
histological evaluation for research purposes.
The 155 patients were followed-up for a median of 116 months (18–252). The
median recipient age was 53 years (21–68), 126 were male (81%); median donor
age was 41 years (16–62); 46% had genotype 1, 31.5% genotype 3, 44 (28%) had
concomitant ALD and 35 (22%) HCC pre-LT and 6 (4%) concomitant HBV infection
(HBV DNA continuously suppressed). Antiviral therapy for HCV was given in 46
patients: 14 achieved SVR. CMV was prospectively evaluated by 3 weekly surveil-
lance blood specimens [17]; CMV infection was treated in 28. Rejection was diag-
nosed by protocol biopsies as previously described [18]: 21% (33 patients) had no
episodes of acute rejection in protocol biopsies, 36% (56 patients) had 1 episode
(14 episodes were not treated), 21% (33 patients) had 2 (3 were not treated),
19% (30 patients) had more than 2 episodes (5 did not receive treatment). Acute
rejection episodes were treated with intravenous 1 g daily methylprednisolone
for 3 days. Histological de novo hepatitis was deﬁned as an increase in alanine
aminotransferase levels (>2 upper normal limit), together with histological
changes consistent with hepatitis without diagnostic features of cellular rejec-
tion, duct loss, or any other cause of liver injury [19]; it was diagnosed in 49
(31.4%).Journal of Hepatology 201Liver biopsies
Liver biopsy samples were formalin ﬁxed, parafﬁn-embedded, and stained with
hematoxylin-eosin, Gordon and Sweet staining for reticulin, and chromotrope
aniline blue. For this study all biopsies were restained with picroSirius red to
ensure comparable staining technique for collagen quantiﬁcation and determina-
tion of CPA by DIA. The stage of disease (ﬁbrosis; 0–6), and the grade of necroin-
ﬂammatory activity were evaluated according to Ishak et al. [20].
The number of liver fragments, length of biopsy, lengths of each fragment
summed, and number of portal tracts per fragment and in total were recorded
[21]. Liver biopsies <12 mm long were excluded. Complete portal tracts were
deﬁned according to Crawford et al. [22].
Histological sections stained with picroSirius red were used for DIA, per-
formed by two authors (P.M. and G.I.) blinded to each other’s results and to clin-
ical information at that time. Interobserver error was also assessed in this way,
such that CPA measurement was repeated if there was a 2% difference or more.
Inadequate staining was determined by the histopathologist and restaining was
performed if this was thought to be needed. The equipment used and CPA mea-
surement were performed as previously described [6]. As described in the original
method, the CPA is an edited measurement: the vascular spaces are one of the
structures manually edited speciﬁcally, thus removed from the CPA measurement
[6].
Acute cellular rejection was graded using the Royal Free Hospital (RFH) score
[23]. Histological de novo hepatitis C(DNHC) was deﬁned as above [19].
Immunosuppression regimens
Maintenance immunosuppression regimens have changed over time but have
been based on cyclosporine and later tacrolimus with or without prednisolone
and azathioprine. These are described in detail in a previous publication [7],
but in essence comprise a period of three randomized studies; initially CYA vs.
TAC monotherapy [24]; then the TMC study, where a cohort received either
CYA or TAC-based triple drug immunosuppression [25]. After the TMC study,
patients transplanted for HCV cirrhosis, in a randomized study received triple
immunosuppression therapy with corticosteroids, TAC and azathioprine (AZA),
or TAC monotherapy, adjusting TAC dosing as previously described [26]. Steroids
were tapered and stopped between 3 and 6 months. MMF substituted AZA if there
was intolerance to AZA or renal dysfunction. Following the trial [26], triple ther-
apy for HCV transplanted cirrhosis patients became standard of care.
There were 106 patients on tacrolimus (TAC), 41 of these on TAC mono-
therapy, and 49 on cyclosporine (CYA) (8 as monotherapy) as maintenance calci-
neurin inhibitor. There were 92 patients on azathioprine (AZA) (42 eventually
discontinued before reaching year 1 post-LT). Another 13 received MMF in substi-
tution of azathioprine due to renal impairment during follow-up. There were 99
patients on steroids immediately post-LT and of these, 56 (36%) were maintained
on steroids beyond 3 months. In our randomized trial in post-transplant HCV
patients, 65 out of the 155 were recruited [26], 34 to tacrolimus monotherapy,
and 31 to tacrolimus, azathioprine and steroids therapy. Another 61 patients
received azathioprine without being randomized in the triple therapy arm, 15
of these discontinued azathioprine before year 1 post-LT.
Acute rejection episodes if histologically moderate/severe were treated with
1 g daily methylprednisolone for 3 days, intravenously. If there was no histolog-
ical improvement in a biopsy 5 days after the ﬁrst, and if was not satisfactorily
resolved by 1 further cycle of 3 doses of methylprednisolone, rejection was trea-
ted with lymphocyte antibodies orthoclone (OKT-3) or antithymocyte globulin
(ATG).
Statistical analysis
Data were analyzed using SPSS (version 20.0; SPSS IBM). The Chi squared test was
used to compare frequencies. Quantitative variables, which were normally dis-
tributed, were expressed as mean values ± standard deviation and non-normally
distributed as median values (range). Signiﬁcance testing was set at p <0.05.
Logistic regression was used to evaluate factors associated with fast vs.
non-fast ﬁbrosers. The ROC analysis was used to compare the performance of
CPA index vs. Ishak index of ﬁbrosis progression with regard to clinical
decompensation. Cox regression was used to compare the occurrence of clinical
decompensation between fast ﬁbrosers and non-fast ﬁbrosers using CPA. Kaplan
Meier-derived curves were used for each statistically signiﬁcant variable in the
multivariate analysis. Time to decompensation was the time from transplantation
to the ﬁrst episode of decompensation. For those with no decompensation,
the interval to last follow-up or death was used as the observation interval.
Follow-up was censored at the time of SVR achievement.3 vol. 58 j 962–968 963
Table 1. Patients’ characteristics with respect to ﬁbrosis progression based on CPA. All these variables were included in the multivariate analysis.
Number of patients n 155 36 119
Recipient Age 53 53 53
Gender (male %) 83 80
Donor Age 41 45 38
Gender (male %) 73 83 62
Concomitant ALD n (%) 44 (28) 10 (28) 34 (28.6)
HCC pre-LT n (%) 35 9 (25) 26 (22)
Cold ischemia time min 677 681 674
Warm ischemia time min 43 45 43
Diabetes pre-LT % 29 33 26
Diabetes post-LT % 32 36 31
Viral load pre-LT
Genotype 1
median
%
1.96 x 106
46
2.4 x 106
44
1.8 x 106
47
CMV infection % 26 6 (17) 20 (17)
Histological de novo hepatitis % 48 21 (56) 28 (23.5)
ACR episodes 0/1/2/>2 30%/39%/14% 19%/35%/24%
Initial immunosuppression TAC/CYA 106/49 26/10 80/39
STEROIDS 99 22 77
AZA/MMF 92/13 24/2 68/11
AZA discontinued n (%) 42 (27) 15 (42) 27 (23)
Follow-up months 116 (18-252) 87 (18-198) 125 (36-252)
Decompensated n (%) 29 (12) 22 (61) 7 (5.9)
Fast fibrosers Non-fast fibrosers
Research ArticleResults
There were 610 biopsies: 587 were evaluated (median number of
biopsies 3/patient), as 23 were less than 12 mm long and were
excluded from analysis: 36 patients had 2 biopsies only, 48 had
3 biopsies, 22 had 4 biopsies, and the remaining 49 patients had
more than 4 biopsies (5–12). Median CPA ﬁbrosis progression rate
was 0.71%/year (0.0–2.6 interquartile range; 2.6%/year upper
quartile). Fibrosis progression according to CPA over time (over
ten years) is shown in Fig. 1. A CPA rate of increase P2.6%/year
(upper quartile) was present in 36 (23%) patients (Fig. 2). Median
progression according to Ishak stage rate of increase was 0.42/
year (interquartile range 0–1; upper quartile 1/year). A stage ratio
P1/year was found in 24 (15%) patients. Stage progression over
time is shown in Fig. 1. Mean stages per year (given for compari-
sonwith previous studies by others) were: at 1 year (1.73), 2 years
(2), 3 years (2.4), 4 years (2.5), 5 years (2.7), 6 years (2.8), 7 years
(2.93), 8 years (3.57), 9 years (3.58), and 10 years (3.6).
During follow-up, 29 (19%) of the 155 patients decompen-
sated at a median of 114 months (15–191) from liver transplan-
tation: the ﬁrst decompensation was ascites and/or hydrothorax
in 19 patients, variceal bleeding in 3, and encephalopathy (PSE) in
5. Two patients decompensated before the second biopsy and
thus were excluded from our study population. Death occurred
in 33 patients (21%) at a median of 80 m (15–195): 18 were liver
related (3 from recurrent HCC).
The demographic and clinical data listed in Table 1 were eval-
uated in the logistic and Cox regression analysis.
The ROC curve for rate of increase of ﬁbrosis (fast vs. non-fast
ﬁbrosers), for the association with decompensation, is shown in
Fig. 3. The AUROC for clinical decompensation was 0.81964 Journal of Hepatology 201(p <0.001, 95% CI 0.71–0.91) for CPA progression, and 0.68
(p = 0.003, 95% CI 0.56–0.81) for Ishak stage rate of increase
(p = 0.67, n.s. in Cox regression).
Using logistic analysis, we studied possible factors associated
with fast ﬁbrosers vs. non-fast ﬁbrosers based on CPA rate of
increase. In the univariate analysis, donor age >40 years
(p = 0.001), non-use of maintenance steroids post-LT (p = 0.035),
non-use or discontinuation of azathioprine within 1 year post-
LT (p = 0.001), and episodes of histological de novo hepatitis
(p = 0.001) were independently associated with fast ﬁbrosis. In
the multivariate analysis, histological de novo hepatitis
(p = 0.016, OR = 3.77, 95% CI 1.65–8.72), non-use or discontinua-
tion of azathioprine (p = 0.004, OR = 3.85, 95% CI 1.25–11.83), and
donor age >40 years (p = 0.026, OR = 1.03, 95% CI 1.006–1.061)
were independently associated with fast ﬁbrosers. With Ishak
stage ﬁbrosis progression, in the multivariate analysis, only histo-
logical de novo hepatitis was associated with fast ﬁbrosers
(p = 0.002, OR = 4.4, 95% CI 1.7–11.07). Comparing the patients
receiving azathioprine within the randomized trial together with
those patients not randomized, the continued use of azathioprine
beyond one year was associated with a low rate of fast ﬁbrosis: 2/
14 vs. 4/30; and clinical decompensation 2/14 vs. 6/30, respec-
tively, in both azathioprine groups.
The time to ﬁrst clinical decompensation was associated in
the univariate analysis with ﬁbrosis rate of increase based on
CPA (p <0.001), Ishak stage ﬁbrosis rate of increase (p = 0.001),
advanced donor age (p = 0.007) and histological de novo hepatitis
C (p = 0.013). In Table 2, the details of the 29 patients who
decompensated are shown. In the multivariate analysis, in Cox
regression the only factor associated with clinical decompensa-
tion was rate of ﬁbrosis increase according to CPA (p = 0.001,3 vol. 58 j 962–968
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Fig. 1. Median ﬁbrosis according to time after liver transplantation based on
CPA and median Ishak stage. 587 biopsies were evaluated (median number of
biopsies 3/patient): 36 patients had 2 biopsies only, 48 had 3 biopsies, 22 had 4
biopsies, and the remaining 49 patients had more than 4 biopsies (5–12). Median
CPA ﬁbrosis progression rate was 0.71%/year. Each box plot shows the median
value, the interquartile range, and the range of CPA each year.
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Fig. 2. CPA change (CPA at one year subtracted from CPA in the latest biopsy)
in each patient vs. time interval between the two biopsies. The upper quartile
of distribution of the ﬁbrosis rates >2.6%/year CPA deﬁned ‘fast ﬁbrosers’.
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Fig. 3. ROC curves of ﬁbrosis rate of increase according to CPA and Ishak stage
for the prediction of clinical decompensation. The AUROC for clinical decom-
pensation was 0.81 (p <0.001, 95% CI 0.71–0.91) for CPA progression and 0.68
(p = 0.003, 95% CI 0.56–0.81) for Ishak stage rate of increase (p = 0.67, n.s. in Cox
regression).
JOURNAL OF HEPATOLOGYOR = 1.2, 95% CI 1.12–1.2). Fig. 4 shows the Kaplan–Meier curves
of fast ﬁbrosers according to CPA vs. ‘non-fast ﬁbrosers’ (both by
Mantel-Cox and Breslow, p = 0.0001).
Using the 3 years (95 patients) and 5-years (64 patients) ﬁxed
intervals after liver transplantation, and the upper quartile of theJournal of Hepatology 201distributions of CPA and Ishak for each time point vs. the other
three quartiles, the time to clinical decompensation was statisti-
cally signiﬁcant only for CPA (p = 0.033 and p = 0.002 in 3 and
5 years, respectively), but not for Ishak stage (p = 0.16 and
p = 0.11 for 3 and 5 years, respectively), suggesting a more sensi-
tive assessment of ﬁbrosis using CPA.
There was no difference between patients with or without
concomitant alcoholic liver disease pre-LT (n = 44) regarding
ﬁbrosis progression. From these 44, 7 male patients were docu-
mented as drinking more than 21 U of alcohol per week post-
LT. All of these patients were fast ﬁbrosers. However, exclusion
of this group from our analysis made no difference in our results
(AUROC 0.816, 95% CI 0.71–0.922).
Of the 47 patients receiving antiviral treatment, 14 achieved
SVR, 33 did not. All of the 14 patients were non-fast ﬁbrosers
before achieving SVR. Patients were censored at the time of
SVR. In the 33 not achieving SVR, 12 (36%) were fast and 21
(64%) non-fast ﬁbrosers. Of the patients who did not receive anti-
viral treatment (108), 28 were fast ﬁbrosers (26%).Discussion
In this paper, we describe for the ﬁrst time, the assessment of
histological progression of ﬁbrosis using collagen quantiﬁcation
morphometrically compared to the rate of increase of Ishak
stage. We evaluated the association of these two different histo-
logical parameters with clinical decompensation as the relevant
end point, to assess the potential clinical applicability of the
methodology. We also performed logistic regression analysis
to identify independent risk factors associated with fast ﬁbro-
sers (deﬁned by rate of CPA increase), due to recurrent HCV
chronic hepatitis after liver transplantation, an evaluation not
previously performed.
CPA at one time point is a histological measurement that
quantiﬁes ﬁbrosis, and relates to clinical outcomes [6,7]. CPA also
correlates with HVPG with wider range of values in patients with
Ishak stage 5/6, showing that cirrhosis can be subclassiﬁed [8]. As
such, it is different from the traditional histological scoring sys-
tems for ﬁbrosis, which assign numerical symbols to descriptive
categories of architectural changes in the biopsy. The numerical
symbols are not quantitatively related, or are they continuous
variables [1]. However, quantitative assessment of collagen is3 vol. 58 j 962–968 965
Table 2. The 29 patients who decompensated are presented with respect to CPA and Ishak stage at year 1, CPA progression per year – deﬁning fast ﬁbrosers – months
to decompensation post-LT, episodes of acute hepatitis (AHC), azathioprine use or discontinuation (D) before year 1 and donor age. Highlighted/in bold are those
variables which are considered to be prognostic for future decompensation: CPA at year 1 >6% (7), use of azathioprine (current work), donor age >40 years, histological
episodes of acute hepatitis (19) and current work.
Patients
no.
Year 1 
CPA
Year 1 
Ishak stage
De novo 
hepatitis
AZA Donor age ΔCPA/year Months to 
decompensation
Decompensation
1 4 2 Yes D 58 30 17 Ascites
2 5 2 Yes D 24 12 19 Ascites
3 4 2 No D 59 12 22 Ascites
4 4 2 No D 69 17 25 Ascites
5 4 2 No No 60 3 27 Ascites
6 5 2 Yes D 49 30 28 PSE
7 7 6 Yes Yes 22 30 30 PSE
8 16 6 Yes No 59 9 30 Ascites
9 7 4 Yes No 58 30 35 Ascites
10 4 0 Yes Yes 55 3 36 Ascites
11 3 3 Yes No 42 10 36 PSE
12 5 3 Yes D 55 28 39 Variceal bleeding
13 6 2 No D 48 1 49 Variceal bleeding
14 8 3 No No 22 3 53 Ascites
15 9 5 Yes No 45 18 67 Ascites
16 6 4 Yes Yes 40 4 73 Ascites
17 2 1 No D 37 1 76 PSE
18 8 3 Yes D 45 10 83 Ascites
19 3 1 No Yes 73 4 84 Ascites
20 13 4 Yes No 65 7 88 Ascites
21 4 2 Yes D 45 6 95 Ascites
22 12 5 No Yes 61 3 101 PSE
23 7 5 Yes No 42 11 105 Ascites
24 1 2 Yes Yes 30 1 129 Ascites
25 4 2 Yes D 33 3 129 Variceal bleeding
26 2 1 No D 51 2 132 PSE
27 1 3 No Yes 45 5 154 Ascites
28 1 2 No D 45 15 165 Ascites
29 3 1 No Yes 43 1 193 Ascites
Research Articlenot a substitute for a descriptive evaluation of architectural
changes in the liver as we have emphasized previously [2,3],
but is an added evaluation.
Fibrosis progression after liver transplantation for hepatitis C
related cirrhosis has been studied previously by several groups
using Ishak or Metavir staging [27–30], but any deﬁnition of fast
ﬁbrosers has been arbitrary. HCV infection after liver transplanta-
tion is universal and chronic liver disease is common, leading to
cirrhosis in 20% or more by 5 years after liver transplantation (LT)
[31,32]. Fibrosis progression rate is rapid and is associated with
older donors [19,33,34], drugs used for immunosuppression
[35–37], diabetes after transplant [38], and episodes of histolog-
ical de novo hepatitis C, deﬁned as an increase in alanine amino-
transferase levels (>2 upper normal limit), together with
histological changes, consistent with hepatitis without diagnostic
features of cellular rejection, duct loss, or any other cause of liver
injury [19].
HCV recurrence is responsible for graft failure, which results
in increased mortality. This clinical course makes the population
transplanted for HCV cirrhosis an appropriate cohort to evaluate
methods for the assessment of ﬁbrosis progression with966 Journal of Hepatology 201relationships with clinical outcomes. Secondly, the increased
ﬁbrosis rate allows a more accurate evaluation of risk factors
associated with the progression of ﬁbrosis.
In our cohort of 155 patients, the only factor predicting clini-
cal decompensation using Cox regression analysis was CPA. Com-
paring Ishak stage and CPA progression rates by AUROC curves
with respect to the ﬁrst episode of clinical decompensation; this
was 0.81 for CPA and 0.68 for Ishak stage ﬁbrosis progression.
This conﬁrms the validity and better performance of using CPA
to assess progression of ﬁbrosis for recurrent HCV chronic hepa-
titis after liver transplantation.
The evaluation of factors by multivariate analysis associated
with fast ﬁbrosers, showed that episodes of histological de novo
hepatitis post-LT, donor age >40 years and non-use or discontin-
uation of azathioprine (within 1 year of transplantation) were
independently associated risk factors. Advanced donor age is well
recognized to be associated with more aggressive HCV disease
and liver disease progression [19,29,39–41]. However, the role
of immunosuppression in HCV recurrence is still under debate.
One study speciﬁcally reported no difference between cyclospor-
ine and tacrolimus in terms of stage progression [42] without3 vol. 58 j 962–968
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Fig. 4. Kaplan–Meier curves of fast ﬁbrosers deﬁned by the upper quartile of
distribution of the ﬁbrosis rates >2.6%/year of CPA and the remainder (non-
fast ﬁbrosers) with respect to the prediction of clinical decompensation.
Clinical decompensation was deﬁned as whichever occurred ﬁrst of either ascites/
hydrothorax or variceal bleeding or encephalopathy, in a cohort of 155 patients
with paired liver biopsies from year 1 after LT onwards.
JOURNAL OF HEPATOLOGYdifferences in severity of HCV recurrence. In a recent review of
immunosuppression in HCV transplantation, tacrolimus was
shown to be better than cyclosporine with better graft and
patient survival [18]. Azathioprine has been associated with
reduced disease progression in observational studies compared
to mycophenolate mofetil [7,19,33,43–47], but there has been
no randomized comparison [18]. In our cohort, the results are
in accordance with our previous published randomised trial
[26], demonstrating a slower onset of histological severe ﬁbrosis
with continued use of azathioprine long term. The similar results
in patients treated with azathioprine, within and without the
randomized study (Supplementary Fig. 1), reinforce the general
observation that azathioprine may be of beneﬁt [2,18].
Importantly in our transplant population, the overall rate of
increase of disease stage described by changes in Ishak stage is
similar or lower than ﬁbrosis rates described by others
[31,40,48], with our median donor age (41) similar to others
[40] (median donor age 42), or even older than those described
in other studies, with a mean donor age of 34 [48]. Indeed, the
ﬁbrosis rates are as low as those published recently in an observa-
tional study in patients receiving sirolimus compared to historical
controls [30]. The mean ﬁbrosis stage in patients receiving siroli-
mus was 0.62 and 1.15 according to Metavir in year 1 and year 2
biopsies, respectively, while ourmean ﬁbrosis Ishak stage was 1.7,
and 2, in years 1 and 2 post-LT, with the same donor age in the two
populations. The relatively low overall rate of increase of disease
stage in our study population most likely reﬂects the use of the
combined therapy of TAC and AZA and/or lower trough levels of
tacrolimus [18], which we found beneﬁcial in our randomised
trial [26]. Another histological feature, which has been described
in a single paper as predictive for ﬁbrosis progression, is activated
stellate cells [49], but the method as yet has to be validated.
In conclusion, the rate of increase of CPA can be used as a
measurement of progression of ﬁbrosis, and is a good predictor
of clinical decompensation, and is better than the rate of increaseJournal of Hepatology 201of Ishak stage. Although liver biopsy is the reference standard for
assessing ﬁbrosis and thus still needs to be done, a quantitative
method of assessing ﬁbrosis, which has clinical signiﬁcance, such
as CPA [7,50], will lead to comparison with non-invasive tests of
ﬁbrosis obviating the need of biopsy in the future. Although, we
studied a transplant population with recurrent HCV, our results
in chronic hepatitis C and B [50] suggest the method is generali-
sable. However, these ﬁndings need to be conﬁrmed by others in
viral and non-viral chronic liver disease before and after trans-
plantation. Our results suggest that CPA can be considered as a
potential histological index for future studies of ﬁbrosis, includ-
ing those for validation of non-invasive markers of ﬁbrosis.Conﬂicts of interest
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